OUR COMPANY
Redox
Pharmaceutical Corporation has patented a family of metallo-organic compounds
with demonstrated effectiveness in antiviral, antibacterial and
anti-inflammatory applications.
These compounds, originally created at the Technion-Israel Institute of Technology, have been
developed by Redox Pharmaceutical Corporation for a variety of medical applications.
One of these
compounds CTC-96, designated Doxovir™, has been prepared in
formulations appropriate for clinical applications. Pre-clinical
tests of Doxovir™ demonstrate excellent efficacy against ophthalmic Herpes
Virus Type 1 and Adenovirus infections as well as anti-inflammatory
capability. An FDA IND approval has been obtained for ophthalmic Herpes application
of Doxovir™. Phase I Clinical study has been completed and Phase II study is pending.
Extensive
research and pre-clinical trials have been conducted on the use of
Doxovir-M™ for Sexually Transmitted Diseases (STDs). The drug has
proven to have potent microbicidal effects on Herpes Virus Type 2
in both tissue culture and animal models. In addition, the drug
has a potent microbicidal effect on HIV in vitro. In tissue
culture and animal studies, the drug exhibits at least partial
microbicidal and full therapeutic effect on human and bovine
Papilloma viruses. Animal safety trials of Doxovir-M™ in vaginal
formulation under GLP conditions were successfully performed.
Preclinical efficacy studies of Doxovir-M™ in
vaginal formulation are currently being planned.
The mechanism
of action of the drug has been explored for HIV and Herpes type 1
and has been found to differ from that of drugs currently
available. Doxovir™ has been shown to be effective against drug
resistant strains of Herpes Viruses and HIV. The mode of action of
the drug indicates that the development of resistance to it by
these viruses should be very rare.
Contact Us | Home
|
